HTA 101: References
Academy of Managed
Care Pharmacy. Format for Formulary Submissions. Version
2.0. Alexandria, VA, October 2002.
Agema WR, Jukema JW,
Zwinderman AH, van der Wall EE. A meta-analysis of the
angiotensin-converting enzyme gene polymorphism and restenosis
after percutaneous transluminal coronary revascularization:
evidence for publication bias. Am Heart J
2002;144(5):760-8.
Agency for Healthcare
Research and Quality. Nominations of topics for evidence-based
practice centers (EPCs). Federal Register 68(18),
January 28, 2003:4213-6.
Anderson, GF, MA
Hall, EP Steinberg. Medical technology assessment and practice
guidelines: their day in court. Am J Pub Health.
1993;83(3):1635-9.
Anderson JE,
Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and
dependence: an evidence-based clinical practice guideline for
tobacco cessation. Chest. 2002;121(3):932-41.
Andersson I,
Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F,
Ljungberg O, Ronstam J, and Sigfusson B. Mammographic Screening
and mortality from breast cancer: The Malmö Mammographic
Screening Trial. BMJ. 1988; 297(6654):943-8.
Anis AH, Rahman T,
Schechter MT. Using pharmacoeconomic analysis to make drug
insurance coverage decisions. Pharmacoeconomics.
1998;13(1 Pt 2):119-26.
Anonymous. Panel questions rules on trauma research. The
New York Times; April 24, 1994:10.
Arnesen T, Nord E.
The value of DALY life: problems with ethics and validity of
disability adjusted life years. BMJ.
2000;320:1398.
Asch SM, Sloss EM, Hogan C,
Brook RH, Kravitz RL. Measuring underuse and necessary care
among elderly Medicare beneficiaries using inpatient and
outpatient claims. JAMA. 2000;284:2325-33.
Aspirin Myocardial
Infarction Study Research Group. A randomized, controlled trial
of aspirin in persons recovered from myocardial infarction.
JAMA. 1980;243(7): 661-9.
Auston I, Cahn MA,
Selden CR. Literature Search Methods for the Development of
Clinical Practice Guidelines. In Clinical Practice
Guideline Development: Methodology Perspectives, McCormick
KA, Moore SR, Siegel RA, 123-7. Rockville Md: Agency for Health
Care Policy and Research, 1994.
Baidas S, Tfayli A,
Bhargava P. Thalidomide: an old drug with new clinical
applications. Cancer Invest.
2002;20(5-6):835-48.
Balk EM, Bonis
PAL, Moskowitz H, et al. Correlation of quality measures with
estimates of treatment effect in meta-analyses of randomized
controlled trials. JAMA. 2002;287:2973-82.
Banta HD, Luce BR.
Health Care Technology and Its Assessment: An International
Perspective. New York, NY: Oxford University Press;
1993.
Basile J. Hypertension
in the elderly: a review of the importance of systolic blood
pressure elevation. J Clin Hypertens.
2002;4(2):108-12.
Beebe B, Rosenfeld AB,
Collins N. An approach to decisions about coverage of
investigational treatments. HMO Practice.
1997;11(2):65-7.
Bekelman JE, Li Y,
Gross CP. Scope and impact of financial conflicts of interest
in biomedical research: a systematic review. JAMA.
2003;289:454-65.
Berger A. High dose
chemotherapy offers little benefit in breast cancer.
BMJ. 1999 May 29;318(7196):1440.
Berger RL, Celli BR,
Meneghetti AL, Bagley PH, et al. Limitations of randomized
clinical trials for evaluating emerging operations: the case of
lung volume reduction surgery. Ann Thorac Surg. 2001
Aug;72(2):649-57.
Bergner M, Bobbitt
RA, Carter WB, Gilson BS. The Sickness Impact Profile:
development and final revision of a health status measure.
Med Care. 1981;19(8):787-805.
Bloom BS, Fendrick AM.
The tension between cost containment and the underutilization
of effective health services. Int J Technol Assess Health
Care. 1996;12:1-8.
Boer GJ, Widner H. Clinical
neurotransplantation: core assessment protocol rather than sham
surgery as control. Brain Res Bull.
2002;58:547-53.
Bossuyt PM, Reitsma
JB, Bruns DE, et al. Towards complete and accurate reporting of
studies of diagnostic accuracy: the STARD initiative. Clin
Chem. 2003;49(1):1-6.
Brenner M, Jones B,
Daneschvar HL, Triff S. New National Emphysema Treatment Trial
paradigm of health care financing administration-sponsored
clinical research trials: advances and dilemmas. J Investig
Med. 2002;Mar;50(2):95-100.
Briggs A, Clark T,
Wolstenholme J, Clarke P. Missing... presumed at random:
cost-analysis of incomplete data. Health Econ.
2003;12:377-92.
Brooks H, Bowers R. The assessment of technology.
Science.1970;222(2):13-20.
Brownman GP.
Development and aftercare of clinical guidelines: the balance
between rigor and pragmatism. JAMA.
2001;286:1509-11.
Bunch WH,
Dvonch VM. The value of functional independence measure scores.
Am J Phys Med Rehab. 1994;73(1):40-3.
Buring JE, Jonas MA,
Hennekens CH. Large and simple randomized trials. In Tools
for Evaluating Health Technologies: Five Background
Papers. US Congress, Office of Technology Assessment,
1995;167-91. BP-H-142. Washington, DC: US Government Printing
Office; 1994.
Busse R, Orvain J,
Velasco M, et al. Best practice in undertaking and reporting
health technology assessments. Int J Technol Assess Health
Care. 2002;18:361-422.
Buxton MJ. Problems in
the economic appraisal of new health technology: the evaluation
of heart transplants in the UK. In Economic Appraisal of
Health Technology in the European Community. Drummond MF,
ed. Oxford, England. Oxford Medical Publications, 1987.
Byford S, Palmer S.
Common errors and controversies in pharmacoeconomic analyses.
Pharmacoeconomics. 1998;13:659-66.
Carlsson P,
Jørgensen T. Scanning the horizon for emerging health
technologies. Int J Technol Assess Health Care.
1998;14:695-704.
Caro JJ, Caro G, Getsios D,
et al. The migraine ACE model: evaluating the impact on time
lost and medical resource use. Headache.
2002;40:282-91.
Cebul RD Randomized,
controlled trials using the metro firm system. Med
Care. 1991;29(suppl. 7):JS9-18.
Center for
Evidence-Based Medicine. http://www.cebm.net/levels_of_evidence.asp
- levels. Accessed June 1, 2003.
Chalmers TC,
Frank CS, Reitman DR. Minimizing the three stages of
publication bias. JAMA.
1990;263(10):1392-5.
Chan L, Topfer L.
Health Technology Assessment on the Net: A Guide to
Internet Sources of Information. Edmonton, Canada: Alberta
Heritage Foundation for Medical Research; June
2003.
Chopra SS.
Industry funding of clinical trials: Benefit or bias?
JAMA. 2003;290:113.
Choudhdry NK,
Stelfox HT, Detsky AS. Relationships between authors of
clinical practice guidelines and the pharmaceutical industry.
Lancet. 2002;287:612-7.
Chow S, Liu J.
Design and Analysis of Clinical Trials. New York, NY:
John Wiley & Sons; 1998.
Clarke M.
Co-Chair, Cochrane Collaboration Steering Group. Personal
communication; July 2, 2003.
Coates &
Jarratt, Inc. Course Workbook: Technology Assessment.
Anticipating the Consequences of Technological Choices.
1992. Washington, DC.
Coleman RE,
Briner WH, Siegel BA. Clinical PET scanning. A short-lived
orphan. Int J Technol Assess Health Care.
1992;8(4):610-22.
Combe B.
Thalidomide: new indications? Joint Bone Spine.
2001;68:582-7.
Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of
evidence and clinical recommendations on the use of
antithrombotic agents. Chest. 1992;102(suppl.
4):305S-11S.
Cooper JD. Paying
the piper: the NETT strikes a sour note. National Emphysema
Treatment Trial. Ann Thorac Surg.
2001;Aug;72(2):330-3.
Coplen SE, Antman
EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of
quinidine therapy for maintenance of sinus rhythm after
cardioversion. A meta-analysis of randomized control trials.
Circulation. 1990;82:1106-16.
Cutler DM,
McClellan M. Is technological change in medicine worth it?
Health Aff. 2001;20(5):11-29.
de Bruin AF, de
Witte LP, Stevens F, Diederiks JP. Sickness Impact Profile: the
state of the art of a generic functional status measure.
Soc Sci Med. 1992;35(8):1003-14.
Deeks JJ.
Systematic reviews in health care: systematic reviews of
evaluations of diagnostic and screening tests. BMJ.
2001;323:157-62.
Detsky AS. Using
cost-effectiveness analysis to improve the efficiency of
allocating funds to clinical trials. Stat Med.
1990;9(1)-2:173-84.
Detsky AS, Naylor
CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations
in the quality of individual randomized trials into
meta-analysis. J Clin Epid.
1992;45(3):255-65.
Deyo RA. Cascade
effects of medical technology. Annu Rev Public Health.
2002;23:23-44.
Deyo RA, Psaty BM,
Simon G, Wagner EH, Omenn GS. The messenger under attack
— intimidation of researchers by special-interest
groups. N Engl J Med.
1997;336(16):1176-80.
Dickersin K. How
important is publication bias? AIDS Educ Prev.
1997;9(suppl 1):15-21.
Dickersin K, Min
YI. Publication bias: the problem that won't go away. Ann N
Y Acad Sci. 1993;703,:135-46.
Dickersin K,
Scherer R, Lefebvre C. Identifying relevant studies for
systematic reviews. BMJ.
1994;309(6964):1286-91.
Djulbegovic
B, Lacevic M, Cantor A, et al. The uncertainty principle and
industry-sponsored research. Lancet
2000;356:635-8.
Dolan P.
Utilitarianism and the measurement and aggregation of
quality-adjusted life years. Health Care Anal.
2001;9(1):65-76.
Doll H.A, Black NA,
Flood AB, McPherson K. Criterion validation of the Nottingham
health profile: patient views of surgery for benign prostatic
hypertrophy. Soc Sci Med.
1993;37(1):115-22.
Donabedian A.
Quality assessment and assurance: unity of purpose, diversity
of means. Inquiry. 1988;25(1):173-92.
Donaldson MS, Sox
HC, Jr, eds. Setting Priorities for Health Technology
Assessment: A Model Process. Washington, DC: National
Academy Press; 1992. Reprinted with permission from the
National Academy of Sciences, courtesy of the National
Academies Press, Washington, DC.
Dougherty CJ.
Ethical perspectives on prospective payment. Hastings
Center Report. 1989;19(January/February):5-11.
Douw K, Vondeling H,
Eskildensen D, Simpson S. Use of the Internet in scanning the
horizon for new and emerging health technologies; a survey
involved in horizon scanning. J Med Internet
Res.2003;5(1):e6.
Drummond MF,
Jefferson TO. Guidelines for authors and peer reviewers of
economic submissions to the BMJ. The BMJ Economic Evaluation
Working Party. BMJ. 1996;313:275-83.
Easterbrook PJ,
Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical
research. Lancet. 1991;337:867-72.
Eckman MH, Levine
HJ, Pauker SG. Decision analytic and cost-effectiveness issues
concerning anticoagulant prophylaxis in heart disease.
Chest. 1992;102, (suppl. 4):538-49S.
Eddy DM. Selecting
technologies for assessment. Int J Technol Assess Health
Care.1989;5(4):485-501.
Eddy DM. A Manual
for Assessing Health Practices & Designing Practice
Policies: The Explicit Approach. Philadelphia, Pa:
American College of Physicians, 1992.
Egger M, Davey
Smith G, Altman DG, eds. Systematic Reviews in Health Care:
Meta-analysis in Context.
2nded.
London, England: BMJ Books; 2001.
Egger M,
Davey Smith G, Sterne JA. Uses and abuses of meta-analysis.
Clin Med. 2001;1:478-84.
Eisenberg JM. Ten lessons for evidence-based technology
assessment. JAMA. 1999;17:1865-9.
Elixhauser A,
Halpern M, Schmier J, Luce BR. Health care CBA and CEA from
1991 to 1996: an updated bibliography. Med Care.
1998;36(suppl. 5):MS1-9,MS18-147.
Ellenberg SS. Do
large, simple trials have a place in the evaluation of aids
therapies? Oncology. 1992;6:55-9,63.
Elwood PC.
British studies of aspirin and myocardial infarction. Am J
Med.1983;74(6A):50-4.
Elwood PC,
Cochrane AL, Burr ML, et al. A randomized controlled trial of
acetyl salicylic acid in the secondary prevention of mortality
from myocardial infarction. BMJ.
1974;1(905):436-40.
Elwood PC,
Sweetnam PM. Aspirin and secondary mortality after myocardial
infarction. Lancet.
1979;2(8156-8157):1313-5.
Enkin M, Keirse
MJNC, Renfrew M, Neilson J. A Guide to Effective Care in
Pregnancy and Childbirth. Second Edition. New York, NY:
Oxford University Press; 1995.
Essink-Bot ML,
Stouthard ME, Bonsel GJ. Generalizability of valuations on
health states collected with the EuroQol©
questionnaire. Health Economics.
1993;2(3):237-46.
EuroQol© Group.
"EuroQol© — A new facility for the
measurement of health related quality of life. Health
Policy.1990;16(3):199-208.
Feeny D, Guyatt
G, Tugwell P, eds. Health care Technology: Effectiveness,
Efficiency, and Public Policy. Montreal, Canada: Institute
for Research on Public Policy; 1986.
ECRI. Health
Technology Forecast. Plymouth Meeting, Pa: ECRI;
2002.
Egger M, Juni P,
Bartlett C, Holenstein F, Sterne J. How important are
comprehensive literature searches and the assessment of trial
quality in systematic reviews? Empirical study. Health
Technol Assess. 2003;7(1):1-76.
Ferguson JH.
NIH consensus conferences: dissemination and impact. Ann N
Y Acad Sci. 1993;703:180-98.
Ferguson JH, Dubinsky M, Kirsch PJ. Court-ordered
reimbursement for unproven medical technology. JAMA.
1993;269(16):2116-21.
Ferguson JH,
Sherman CR. Panelists' views of 68 NIH consensus
conference. Int J Technol Assess Health
Care.2001;17(4):542-58.
Ferguson TB
Jr, Peterson ED, Coombs LP, et al. Use of continuous quality
improvement to increase use of process measures in patients
undergoing coronary artery bypass graft surgery: A randomized
controlled trial. JAMA. 2003;290:49-56.
Fineberg HV,
Bauman R, Sosman M. Computerized cranial tomography: effect on
diagnostic and therapeutic plans. JAMA.
1977;238(3):224-30.
Fink A, Kosecoff J,
Chassin M, Brook RH. Consensus methods: characteristics and
guidelines for use. Am J Pub Health.
1984;74(9):979-83.
Fishman A,
Martinez F, Naunheim K, et al; National Emphysema Treatment
Trial Research Group. A randomized trial comparing
lung-volume-reduction surgery with medical therapy for severe
emphysema. N Engl J Med. 2003 May
22;348(21):2059-73.
Fletcher SW.
Whither scientific deliberation in health policy
recommendations? N Engl J Med.
1997;16:1180-3.
Fletcher SW,
Colditz GA. Failure of estrogen plus progestin therapy for
prevention. JAMA. 2002;288:366-8.
Forrow L, Taylor
WC, Arnold RM. Absolutely relative: how research results are
summarized can affect treatment decisions. Am J Med.
1992;92(2):121-94.
Foulds J.
Effectiveness of smoking cessation initiatives. Smoking
cessation services show good return on investment.
BMJ. 2002 Mar 9;324(7337):608-9.
Friedberg M,
Saffran B, Stinson TJ, et al. Evaluation of conflict of
interest in economic analyses of new drugs used in oncology.
JAMA. 1999;282:1453-7.
Freiman JA,
Chalmers TC, Smith H, Jr., Kuebler RR. The importance of beta,
the Type II error and sample size in the design and
interpretation of the randomized controlled trial. survey of 71
"negative" trials. N Engl J Med.
1978;299(13):690-4.
Fye WB. The power of
clinical trials and guidelines,and the challenge of conflicts
of interest. J Am Coll Cardiol.
2003;41:1237-42.
Gallagher M,
Hares T, Spencer J, Bradshaw C, Webb I. The nominal group
technique: a research tool for general practice? Family
Practice. 1993;10(1):76-81.
Gann MJ, Restuccia
JD. Total quality management in health care: a view of current
and potential research. Med Care Rev.
1994;51(4):467-500.
Gazelle GS,
Hunink MG, Kuntz KM, et al. Cost-effectiveness of hepatic
metastasectomy in patients with metastatic colorectal
carcinoma: a state-transition Monte Carlo decision analysis.
Ann Surg. 2003;237:544-55.
Gelijns A,
Rosenberg N. The dynamics of technological change in medicine.
Health Aff.
1994;13(3):28-46.
Gerard K, Mooney G. QALY league tables: handle with care.
Health Economics. 1993;2(1):59-64.
Gibson JL, Martin
DK, Singer PA. Priority setting for new technologies in
medicine: a transdisciplinary study. BMC Health Serv
Res. 2002;2(1):14
Glennie JL,
Torrance GW, Baladi JF, et al. The revised Canadian guidelines
for the economic evaluation of pharmaceuticals.
Pharmacoeconomics. 1999;15(5):459-68.
Gold JA, Zaremski MJ,
Lev ER, Shefrin DH. Daubert v. Merrell Dow. The Supreme Court
tackles scientific evidence in the courtroom. JAMA.
1993;270(24):2964-7.
Gold MR, Stevenson D,
Fryback DG. HALYS and QALYS and DALYS, oh my: similarities and
differences in summary measures of population health. Annu
Rev Public Health. 2002;23:115-34.
Gold MR, Siegel JE,
Russell LB, Weinstein MC. Cost-Effectiveness in Health and
Medicine. New York, NY: Oxford University Press;
1996.
Goldberg HI,
Cummings MA, Steinberg EP, et al. Deliberations on the
dissemination of PORT products: translating research findings
into improved patient outcomes. Med Care.
1994;32(suppl. 7):JS90-110.
Goodman C, ed.
Medical Technology Assessment Directory: A Pilot Reference
to Organizations, Assessments, and Information Resources.
Washington, DC: Institute of Medicine; 1988.
Goodman C. It's
time to rethink health care technology assessment. Int J
Technol Assess Health Care. 1992;8(2):335-58.
Goodman C.
Literature Searching and Evidence Interpretation for
Assessing Health Care Practices. Stockholm, Sweden:
Swedish Council on Technology Assessment in Health Care;
1993.
Goodman C. The
moving target problem and other lessons from percutaneous
transluminal coronary angioplasty. In: A Szczepura, Kankaanpää
J. Assessment of Health Care Technologies: Case Studies,
Key Concepts and Strategic Issues. New York, NY: John
Wiley & Sons; 1996:29-65.
Goodman C,
Baratz SR, eds. Improving Consensus Development for Health
Technology Assessment: An International Perspective.
Washington, DC: National Academy Press; 1990.
Goodman
C, Snider G, Flynn K. Health Care Technology Assessment in
VA. Boston, Mass: Management Decision and Research Center.
Washington, DC: Health Services Research and Development
Service; 1996.
Goodman CS.
Healthcare technology assessment: methods, framework, and role
in policy making. Am J Manag Care.
1998;4:SP200-14.
Goodman
CS. Technology assessment in healthcare: a means for pursuing
the goals of biomedical engineering. Med Biolog Eng
Comput. 1993;31(1):HTA3-10.
Gøtsche PC.
Multiple publication of reports of drug trials. Eur J Clin
Pharmacol. 1989;36:429-32.
Graves N, Walker
D, Raine R, et al. Cost data for individual patients included
in clinical studies: no amount of statistical analysis can
compensate for inadequate costing methods. Health
Economics. 2002;11:735-9.
Gregorian RS,
Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM.
Antidepressant-induced sexual dysfunction. Ann
Pharmacother. 2002;36:1577-89.
Grimes DA.
Technology follies: the uncritical acceptance of medical
innovation. JAMA. 1993;269(23):3030-3.
Guyatt GH, Haynes
RB, Jaeschke RZ, et al. Users' guide to the medical literature,
XXV: Evidence-based medicine: principles for applying the
users' guides to patient care. Evidence-Based Medicine Working
Group. JAMA. 2000;284:1290-6.
Harbour R,
Miller J. A new system for grading recommendations in evidence
based guidelines. BMJ. 2001;323:334-6.
Harper G,
Townsend J, Buxton M. The preliminary economic evaluation of
the health technologies for the prioritization of health
technology assessments. Int J Technol Assess Health
Care. 1998;14:652-62.
Harris RP,
Helfand M, Woolf SH, et al. Current methods of the US
Preventive Services Task Force. A review of the process. Am
J Prev Med. 2001;20(3S):21-35.
Hasselblad V,
Hedges LV. Meta-analysis of screening and diagnostic tests.
Psychol Bull. 1995;117(1): 167-78.
Hayward RSA.,
Wilson MC, Tunis SR, Bass EB, Guyatt G. Users' guides to the
medical literature. VIII. How to use clinical practice
guidelines. A. Are the recommendations valid? JAMA.
1995;274(7):570-4.
Heitman E.
Ethical issues in technology assessment. Conceptual categories
and procedural considerations. Int J Technol Assess Health
Care. 1998;14(3):544-66.
Henry D, Lopert R.
Pharmacoeconomics and policy decisions: The Australian health
care system. Clin Ther. 1999;21:909-15.
Henshall C,
Koch P, von Below GC, Boer A, et al. Health technology
assessment in policy and practice. Int J Technol Assess
Health Care. 2002;18(2):447-55.
Hilborne LH,
Leape LL, Kahan JP, Park RE, Kamberg CJ, Brook RH.
Percutaneous Transluminal Coronary Angioplasty: A
Literature Review of Ratings of Appropriateness and
Necessity. Santa Monica, Ca: RAND; 1991.
Hill SR, Mitchell AS,
Henry DA. Problems with the interpretation of pharmacoeconomic
analyses: a review of submissions to the Australian
Pharmaceutical Benefits Scheme. JAMA.
2000;283(16):2116-21.
Hjelmgren J,
Berggren F, Andersson F. Health economic
guidelines--similarities, differences and some implications.
Value Health. 2001;4(3):225-50.
Hoffman B. Is
there a technological imperative in health care? Int J
Technol Assess Health Care.
2002;18(3):675-89.
Hogness JR,Van
Antwerp M. The Artificial Heart: Prototypes, Policies, and
Patients. Washington, DC: National Academy Press; 1991.
Reprinted with permission from the National Academy of
Sciences, courtesy of the National Academies Press, Washington,
DC.
Horng S, Miller FG.
Ethical framework for the use of sham procedures in clinical
trials. Crit Care Med. 2003;31(suppl.
3):S126-30.
Hunt DL, Jaeschke R,
McKibbon KA. Users' guides to the medical literature: XXI.
Using electronic health information resources in evidence-based
practice. Evidence-Based Medicine Working Group. JAMA
2000;283(14):1875-9.
International Network of Agencies for
Health Technology Assessment (INAHTA). http://www.inahta.org/.
Accessed June 1, 2003.
Institute for the Future.
Health & Health Care 2010. The Forecast, The
challenge. San Francisco, Ca: Jossey-Bass Publishers;
2000.
Institute of Medicine. Assessing
Medical Technologies. Washington, DC: National Academy
Press; 1985.
Institute of Medicine. Assessment of
Diagnostic Technology in Health Care. Rationale,Methods,
Problems, and Directions. Washington, DC: National Academy
Press; 1989. Reprinted with permission from the National
Academy of Sciences, courtesy of the National Academies Press,
Washington, DC.
Institute of Medicine. Consensus
Development at the NIH: Improving the Program. Washington,
DC: National Academy Press; 1990.
Institute of Medicine, Committee on
Quality of Health Care in America. Crossing the Quality
Chasm: A New Health System for the 21st Century.
Washington, DC: National Academy Press; 2001.
International Committee of Medical Journal
Writers. Conflict of interest. Lancet.
1993;341(8847):742-3.
International Committee of Medical Journal
Writers. Uniform requirements for manuscripts submitted to
biomedical journals. N Engl J Med.
1997;336:309-15.
Ioannidis JPA.
Effects of statistical significance of results on the time to
completion and publication of randomized efficacy trials.
JAMA. 1998;279:281-6.
Irwig L, Tosteson
AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, Mosteller F.
Guidelines for meta-analyses evaluating diagnostic tests.
Ann Intern Med. 1994;120(8):667-76.
Jadad AR, Moore RA,
Carrol D, et al. Asssessing the quality of reports of
randomized clinical trials: Is blinding necessary?
Controlled Clin Trials. 1996;17:1-12.
Jairath N,
Weinstein J. The Delphi methodology (part two): a useful
administrative approach. Can J Nurs Admin.
1994;7(4):7-20.
Jenkinson C,
Fitzpatrick R, Argyle M. The Nottingham Health Profile: an
analysis of its sensitivity to differentiating illness groups.
Soc Sci Med. 1988;27(12):1411-4.
Johannesson
M, Pliskin JS, Weinstein MC. Are healthy-years equivalents an
improvement over quality-adjusted life years? Med Dec
Making. 1993;13(4):281-6.
Jorenby DE,
Leischow SJ, Nides MA, Rennard SI, et al. A controlled trial of
sustained-release bupropion, a nicotine patch, or both for
smoking cessation. N Engl J Med. 1999 Mar
4;340(9):685-91.
Juni P, Witschi A,
Bloch R, Egger M. The hazards of scoring the quality of
clinical trials for meta-analysis. JAMA.
1999;182:1054-60.
Kaden RJ, Vaul JH,
Palazola PA. Negotiating payment for new technology purchases.
Healthc Financ Manage.
2002;56(12):44-8.
Kahan JP, Bernstein
SJ, Leape LL, Hilborne LH, Park RE, Parker L, Kamberg CJ, Brook
RH. Measuring the necessity of medical procedures. Med
Care. 1994;32(4):357-65.
Kahan JP, Kanouse
DE, Winkler JD. Stylistic variations in National Institutes of
Health consensus statements, 1979-1983. Int J Technol
Assess Health Care. 1988;4(2):289-304.
Kaplan RM,
Anderson JP. A general health policy model: update and
applications. Health Services Research.
1988;23,:203-35.
Kaplan RM,
Anderson JP, Wu AW, Mathews WC, Kozin F, Orenstein D. The
Quality of Well-being Scale: applications in AIDS, cystic
fibrosis, and arthritis. Med Care. 1989;27(suppl.
3):S27-43.
Kassirer JP,
Angell M. Financial conflicts of interest in biomedical
research. N Engl J Med. 1993;329:570-1.
Kassirer JP,
Angell M. The journal's policy on cost-effectiveness analyses.
N Engl J Med. 1994;331:669-70.
Katz S, Downs TD,
Cash HR, Grotz RC. Progress in the development of the index of
ADL. Gerontologist. 1970;10(part
I):20-30.
Kazis LE, Anderson
JJ, Meenan RF. Effect sizes for interpreting changes in health
status. Med Care. 1989;27(suppl.
3):S178-189.
Kim S, Losina E,
Solomon DH, Wright J, Katz JN. Effectiveness of clinical
pathways for total knee and total hip arthroplasty: literature
review. J Arthroplasty.
2003;18(1):69-74.
Kleinman LC,
Kosecoff J, Dubois RW, Brook RH. The medical appropriateness of
tympanostomy tubes proposed for children younger than 16 years
in the United States. JAMA.
1994;271(16):1250-5.
Kwan J, Sandercock P.
In-hospital care pathways for stroke: a Cochrane systematic
review. Stroke. 2003;34(2):587-8.
Laird NM, Mosteller
F. Some statistical methods for combining experimental results.
Int J Technol Assess Health Care.
1990;6(1):5-30.
Lalezari JP,
Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion
inhibitor, for drug-resistant HIV infection in North and South
America. N Engl J Med.
2003;348:2175-85.
Lara ME, Goodman C,
eds. National Priorities for the Assessment of Clinical
Conditions and Medical Technologies. Washington, DC:
National Academy Press; 1990.
Lau J, Antman EM,
Jiminez-Silva J, Kupelnick B, Mosteller F, Chalmers TC.
Cumulative meta-analysis of therapeutic trials for myocardial
infarction. N Engl J Med. 1992;327(4):248-54.
Copyright © 1992 Massachusetts Medical Society. All rights
reserved.
Lazaridis EN,
Rudberg MA, Furner MA, Cassel CK. Do activities of daily living
have a hierarchical structure? An analysis using the
longitudinal study of aging. J Gerontol.
1994;49(2):M47-51.
The Lewin Group.
Outlook for Medical Technology Innovation. Report 2: The
Medicare Payment Process and Patient Access to Technology.
Washington, DC: AdvaMed; 2000.
The Lewin Group.
Outlook for Medical Technology Innovation. Report 4: The
Impact of Regulation and Market Dynamics on Innovation.
Washington, DC: AdvaMed; 2001.
The Lewin Group.
The Clinical Review Process Conducted by Group Purchasing
Organizations and Health Systems. Prepared for the Health
Industry Group Purchasing Association, April
2002.
Linacre JM,
Heinemann AW, Wright BD, Granger CV, Hamilton BB. The structure
and stability of the Functional Independence Measure. Arch
Phys Med Rehab. 1994;75(2):127-32.
Littenberg B,
Moses LE. Estimating diagnostic accuracy from multiple
conflicting reports: a new meta-analytic method. Med Dec
Making. 1993;13(4):313-21.
Lo B, Wolf LE, Berkeley
A. Conflict-of-interest policies for investigators in clinical
trials. N Engl J Med.
2000;343(22):1616-20.
Lohr KN, ed.
Institute of Medicine. Medicare: a Strategy for Quality
Assurance. Volume I. Washington, DC. National Academy
Press; 1990.
Lohr KN, Rettig RA,
eds. Quality of Care and Technology Assessment. Report of a
Forum of the Council on Health Care Technology.
Washington, DC: National Academy Press; 1988.
Lyles A. Direct
marketing of pharmaceuticals to consumers. Annu Rev Public
Health. 2002;23:73-91.
MacLean CH,
Morton SC, Ofman JJ, Roth EA, Shekelle PG. How useful are
unpublished data from the Food and Drug Administration in
meta-analysis? J Clin Epidemiol. 2003
Jan;56(1):44-51.
Mason JM. Cost-per
QALY league tables: Their roles in pharmacoeconomic analysis.
Pharmacoeconomics. 1994;5:472-81.
Massa T. An
industry perspective: challenges in the development and
regulation of drug-device combination products. In Hanna K,
Manning FJ, Bouxsein P, Pope A, eds. Innovation and
Invention in Medical Devices. Workshop Summary. Institute of
Medicine. Washington, DC: National Academy Press;
2002:16-20.
Maynard A.
Developing the health care market. Econ J.
1991;101:1277-86.
McDonald IG.
Quality assurance and technology assessment: pieces of a larger
puzzle. J Qual Clin Pract.
2000;20(2-3):87-94.
McGivney WT.
Proposal for assuring technology competency and leadership in
medicine. JNCI. 1992;84(10):742-5.
McGlynn EA,
Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA.
The quality of health care delivered to adults in the United
States. N Engl J Med. 2003 Jun
26;348(26):2635-45.
McGlynn EA,
Kosecoff J, Brook RH. Format and conduct of consensus
development conferences. Multi-nation comparison. Int J
Technol Assess Health Care.
1990;6(3):450-69.
McHorney CA,
Ware JE, Jr, Lu JF, Sherbourne CD. The MOS 36-item short-form
health survey (SF-36): III. Tests of data quality, scaling
assumptions, and reliability across diverse patient groups.
Med Care. 1994;32(1):40-66.
McKinlay JB.
From "promising report" to "standard procedure": seven stages
in the career of a medical innovation. Milbank Memorial
Fund Quarterly. 1981;59(3):374-411.
McNeil BJ.
Shattuck Lecture −Hidden barriers to improvement in
the quality of care. N Engl J Med.
2001;345:1612-20.
Medical
Technology Leadership Forum. MTLF Summit: Conditional
Coverage of Investigational Technologies. Prepared by The
Lewin Group. Washington, DC; October 1999.
Medicare
Payment Advisory Commission. Accounting for new technology in
hospital prospective payment systems. In Report to the
Congress: Medicare Payment Policy. Washington, DC:
Medicare Payment Advisory Commission;
2001;33-45.
Meenan RF, Mason
JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2. The content and
properties of revised and expanded arthritis impact measurement
scales health status questionnaire. Arthritis and
Rheumatism. 1992;35(1):1-10.
Mehrez A, Gafni
A. Healthy-years equivalents versus quality-adjusted life
years: In pursuit of progress. Med Dec Making.
1993;13(4):287-92.
Mello MM, Brennan
TA. The controversy over high-dose chemotherapy with autologous
bone marrow transplant for breast cancer. Health Aff.
2001;20(5):101-17.
Mendelson DN,
Goodman CS, Ahn R, Rubin RJ. Outcomes and effectiveness
research in the private sector and role of the Agency for
Health Care Policy and Research. Health Aff.
1998;17(5):75-90.
Merigan TC. You
can teach an old dog new tricks: how AIDS trials are pioneering
new strategies. N Engl J Med 323.
1990(19):1341-3.
Mills RM, Jr, M.
Kalan J. Developing a rational management strategy for angina
pectoris after coronary bypass surgery: a clinical decision
analysis. Clin Cardiol.
1991;14(3):191-7.
Miranda B,
Matesanz R. International issues in transplantation. Setting
the scene and flagging the most urgent and controversial
issues. Ann N Y Acad Sci.
1998;862:129-43.
Mittman BS, Siu
AL. Changing provider behavior: applying research on outcomes
and effectiveness in health care. In Improving Health
Policy and Management: Nine Critical Research Issues for the
1990s. Shortell SM, Reinhardt UE eds. 195-226. Ann Arbor,
Mich: Health Administration Press; 1992.
Mittman
BS, Tonesk X, Jacobson PD. Implementing clinical practice
guidelines: social influence strategies and practitioner
behaviour change. Qual Rev Bull
1992;18:413-21.
Moher D, Cook DJ,
Eastwood S, Olkin I, et al. Improving the quality of reports of
meta-analyses of randomized controlled trials: the QUOROM
statement. Quality of reporting of meta-analyses.
Lancet. 1999;354:1896-900.
Moher D, Pham B,
Jones A, et al. Does quality of reports of randomised trials
affect estimates of intervention efficacy reported in
nmeta-analyses? Lancet 1998;352:609-13.
Moher D, Dulberg
CS, Wells GA. Statistical power, sample size, and their
reporting in randomized controlled trials. JAMA.
1994;272:122-4.
Moher D, Jadad AR,
Tugwell R. Assessing the quality of randomized controlled
trials. Current issues and future directions. Int J Technol
Assess Health Care. 1996;12(2):195-208.
Moher D, Schulz KF,
Altman D, et al. The CONSORT statement: revised recommendations
for improving the quality of reports of parallel-group
randomized trials. JAMA.
2001;285(15):1987-91.
Moseley JB,
O'Malley K, Petersen NJ, et al. A controlled trial of
arthroscopic surgery for osteoarthritis of the knee. N Engl
J Med. 2002;347:81-8.
Mowatt G, Bower
DJ, Brebner JA, Cairns JA, Grant AM, McKee L. When and how to
assess fast-changing technologies: a comparative study of
medical applications of four generic technologies. Health
Technology Assessment. 1997;1(14).
Murphy MK, Black
NA, Lamping DL, et al. Consensus development methods, and their
use in clinical guideline development. Health Technol
Assessment. 1998;2(3):i-iv, 1-88.
National
Academy of Engineering, Committee on Public Engineering policy.
A Study of Technology Assessment. Washington, DC: US
Government Printing Office; 1969.
National
Committee for Quality Assurance. The State of Health Care
Quality: 2003. Washington, DC, 2003.
National
Institute for Clinical Evidence. Guidance for Manufacturers
and Sponsors. Technology Appraisals Process Series No. 5.
London, June 2001.
National Library of Medicine, National
Information Center on Health Services Research & Health
Care Technology. Etext on Health Technology Assessment
(HTA) Information Resources. http://www.nlm.nih.gov/archive//2060905/nichsr/ehta/ehta.html
. Accessed June 1, 2003.
National
Research Council, Committee on the Life Sciences and Social
Policy. Assessing Biomedical Technologies: An Inquiry into
the Nature of the Process. Washington, DC: National
Academy of Sciences; 1975.
Neuhauser D,
Lewicki AM. What do we gain from the sixth stool guaiac? N
Engl J Med. 1975;293:226-8. Copyright © 1975
Massachusetts Medical Society. All rights reserved.
Neumann PJ,
Claxton K, Weinstein MC. The FDA's regulation of health
economic information. Health Aff.
2000;19(5):129-37.
Newcomer LN.
Defining experimental therapy – a third party payer's
dilemma. N Engl J Med 323.
1990(24):1702-4.
Newhouse JP.
Medical care costs: how much welfare loss? J Econ
Perspect. 1992;6(3):3-21.
NHS Centre for Reviews
and Dissemination. Undertaking Systematic Reviews of
Research on Effectiveness. CRD Guidelines for Those Carrying
Out or Commissioning Reviews. CRD Report 4. University of
York, UK; 1996.
Nixon J, Stoykova B,
Glanville J, Christie J, Drummond M, Kleijnen J. The U.K. NHS
Economic Evaluation Database. Economic issues in evaluations of
health technology. Int J Technol Assess Health Care.
2000;731-42.
Nord E. The QALY
– a measure of social value rather than individual
utility? Health Econ. 1994;3(2):89-93.
Normand SL.
Meta-analysis: formulating, evaluating, combining, and
reporting. Stat Med.
1999;18:321-59.
O'Brien BJ,
Buxton MJ, Patterson, DL. Relationship between functional
status and health-related quality-of-life after myocardial
infarction. Med Care.
1993;31(10):950-5.
Olson CM. Consensus
statements: applying structure. JAMA.
1995;273(1):72-3.
Olson O, Gøtzsche
PC. Cochrane review on screening for breast cancer with
mammography. Lancet. 2001;358:1340-2.
Oxman AD, Sackett
DL, Guyatt GH. Users' guides to the medical literature. I. How
to get started. JAMA.
1993;270(17):2093-5.
Passamani E.
Clinical trials: are they ethical? N Engl J Med.
1991;324(22):1589-92.
Patrick DL,
Deyo RA. Generic and disease-specific measures in assessing
health status and quality of life. Mel Care.
1989;27(suppl. 3):S217-32.
Patrick DL,
Starks HE, Cain KC, Uhlmann RF, Pearlman RA. Measuring
preferences for health states
worse than death. Med Dec Making.
1994;14(1):9-18.
Pauker SG, Kassirer,
JP. Decision analysis. N Engl J Med.
1987;316(5):250-8.
Petitti DB.
Approaches to heterogeneity in meta-analysis. Stat
Med. 2001;20:3625-33.
Peto R, Collins R,
Gray R. Large-scale randomized evidence: large, simple trials
and overviews of trials. Ann N Y Acad Sci.
1993;703:314-40.
Phelps CE, Mooney
C. Correction and update on 'priority setting in medical
technology assessment.'Medical
Care. 1992;30(8):744-51.
Phelps CE,
Mushlin AI. On the (near) equivalence of cost-effectiveness and
cost-benefit analyses. Int J Technol Assess Health
Care. 1991;7:12-21.
Phillips WR.
Clinical policies: making conflicts of interest explicit. Task
force on clinical policies for patient care.
American Academy of Family Physicians. JAMA.
1994;272(19):1479.
Pilnick A,
Dingwall R, Starkey K. Disease management: definitions,
difficulties and future directions.
Bull World Health
Organ.2001;79(8):755-63.
Poe NR, Griffiths RI.
Clinical-economic Trials. In Tools for Evaluating Health
Technologies: Five Background Papers. US Congress, Office
of Technology Assessment, BP-H-142, 125-49. Washington, DC: US
Government Printing Office; 1995.
Ramsey SD, Berry
K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE; National
Emphysema Treatment Trial Research Group. Cost effectiveness of
lung-volume-reduction surgery for patients with severe
emphysema. N Engl J Med.
2003;348(21):2092-102.
Reiser SJ.
Criteria for standard versus experimental therapy. Health
Aff. 1994;13(3):127-36.
Relman AS.
Financial incentives in clinical investigation. N Engl J
Med. 1989;320:933-34.
Rettig RA.
Health Care in Transition: Technology Assessment in the
Private Sector. Santa Monica, Ca: RAND;
1997.
Rettig RA,
Levinsky NG, eds. Kidney Failure and the Federal
Government. Washington, DC: National Academy Press;
1991.
Reuzel RP, van
der Wilt GJ, ten Have HA, de Vries Robbe PF. Interactive
technology assessment and wide reflective equilibrium. J
Med Philos. 2001;26(3):245-61.
Richardson P,
Hideshima T, Anderson K. Thalidomide: emerging role in cancer
medicine. Annu Rev Med. 2002;53;629-57.
Rothenberg,
Carbone DP, Johnson DH. Improving the evaluation of new cancer
treatments: challenges and opportunities. Nat Rev
Cancer. 2003;3:303-9.
Rothman KJ,
Michels KB. The continuing unethical use of placebo controls.
N Engl J Med. 1994;331:394-7.
Rossouw JE,
Anderson GL, Prentice RL, et al. Risks and benefits of estrogen
plus progestin in healthy postmenopausal women: principal
results From the Women's Health Initiative randomized
controlled trial. JAMA.
2002;288:321-33.
RTI
International-University of North Carolina Evidence-based
Practice Center. Systems to Rate the Strength of Scientific
Evidence. Evidence Report/Technology Assessment Number 47.
AHRQ Publication No. 02-E016, Rockville, Md: Agency for
Healthcare Research and Quality, April 2002.
Sassi, F. Setting
priorities for the evaluation of health interventions: when
theory does not meet practice. Health Policy.
2003;63:141-54.
Sackett DL,
Richardson WS, Rosenberg W, Haynes RB. Evidence-Based
Medicine. New York, NY: Churchill Livingstone,
1997.
Sadock J, Tolman
ED. Capital equipment budgeting: changing an art to a science.
J Healthc Resour Manag.
1997;15(8):16-21.
Schauffler HH,
Barker DC, Orleans CT. Medicaid coverage for tobacco-dependence
treatments. Health Aff. 2001;20(1):298-303.
Schulz KF,
Chalmers I, Hayes RJ, Altman DG Empirical evidence of bias:
dimensions of methodological quality associated with effects in
controlled trials. JAMA.
1995;273:408-12.
Schwappach DL.
Resource allocation, social values and the QALY: a review of
the debate and empirical evidence. Health Expect.
2002;5(3):210-22.
Sharf BF. Out of
the closet and into the legislature: breast cancer stories.
Health Aff. 2001;20(1):213-8.
Sheingold, SH.
Technology assessment, coverage decisions, and conflict: the
role of guidelines. Am J Manag Care.
1998;4:SP117-25.
Shekelle P,
Eccles MP, Grimshaw JM, Woolf SH. When should clinical
guidelines be updated? BMJ.
2001;323:155-7.
Shekelle PG,
Ortiz E, Rhodes S, Morton SC, Eccles MP, Grimshaw JM, Woolf SH.
Validity of the Agency for Healthcare Research and Quality
clinical practice guidelines: how quickly do guidelines become
outdated? JAMA. 2001;286:1461-7.
Singer SJ,
Bergthold LA. Prospects for improved decision making about
medical necessity. Health Aff.
2001;20(1):200-6.
Soto J. Health
economic evaluations using decision analytic modeling.
Principles and practices--utilization of a checklist to their
development and appraisal. Int J Technol Assess Health
Care. 2002;18:94-111.
Soumerai SB,
Lipton HL. Computer-based drug-utilization review –
risk, benefit, or boondoggle? N Engl J Med.
1995;332:1641-5.
Spilker B.
Guide to Clinical Trials. New York, NY: Raven Press,
1991.
Spilker B.
Quality of Life and Pharmacoeconomics in Clinical
Trials. Philadelphia, Pa: Lippincott Williams &
Wilkins, 1995.
Steinberg EP.
Cost-effectiveness analyses. N Engl J Med.
1995;332:123.
Steinberg EP,
Tielsch JM, Schein OD, Javitt JC, et al. The VF-14. An index of
functional impairment in patients with cataract. Arch
Ophthal. 1994;112(5):630-8.
Sterne JA, Egger
M, Smith GD. Systematic reviews in health care: investigating
and dealing with publication and other biases in meta-analysis.
BMJ. 2001;323:101-5.
Stevens A,
Robert G, Packer C. Early warning of new health care
technologies in the United Kingdom. Int J Technol Assess
Health Care. 1998;14:680-6.
Stone GW, Teirstein
PS, Rubenstein R, et al. A prospective, multicenter, randomized
trial of percutaneous transmyocardial laser revascularization
in patients with nonrecanalizable chronic total occlusions.
J Am Coll Cardiol. 2002;39:1581-7.
Stroup DF, Berlin
JA, Morton SC, et al. Meta-analysis of observational studies in
epidemiology. A proposal for reporting. JAMA.
2000;283:2008-12.
Stryer D, Bero
LA. Characteristics of materials distributed by drug companies.
An evaluation of appropriateness. J Gen Intern Med.
1996;11(10):575-83.
Suarez-Almazor
ME, Belseck E, Homik J, et al. Identifying clinical trials in
the medical literature with electronic databases: MEDLINE alone
is not enough. Control Clin Trials.
2000;21:476-87.
Taylor KS.
Hospital tech assessment teams field requests − and
politics. Hosp Health Netw.
1994;68(16):58.
Taylor RS, Hutton
J, Culyer AJ. Developing the revised NICE appraisal technical
guidance to manufacturers and sponsors: opportunity or threat?
Pharmacoeconomics. 2002;20:1031-8.
Thacker SB.
Meta-analysis: A quantitative approach to research integration.
JAMA. 1988; 259(11):1685-9.
Thamer M, Ray NF,
Henderson SC, et al. Influence of the NIH Consensus Conference
on Helicobacter pylori on physician prescribing among a
Medicaid population. Med Care.
1998;36(5):646-60.
The Coronary
Drug Project Research Group. Aspirin in coronary heart disease.
J Chron Dis. 1976;29(10):625-42.
The Ischemic
Optic Neuropathy Decompression Trial Research Group. Optic
nerve decompression surgery for nonarteritic anterior ischemic
optic neuropathy (NAION) is not effective and may be harmful.
JAMA. 1995;273(8):625-32.
The
Nuremberg Code, from Trials of War Criminals Before the
Nuremberg Military Tribunals under Control Council Law.
2(10):181-82. Washington, DC: US Government Printing Office;
1949.
The
Persantine-Aspirin Reinfarction Study Research Group.
Persantine and aspirin in coronary heart disease.
Circulation. 1980;62(3):449-61.
Thornbury JR,
Fryback DG. Technology assessment – An American view.
Eur J Radiol. 1992;14(2):147-56.
Thornquist MD,
Urban N, Tseng A, Edelstein C, Lund B, Omenn GS. Research cost
analyses to aid in decision making in the conduct of a large
prevention trial, CARET. Carotene and Retinol Efficacy Trial.
Control Clin Trials. 1993;14(4):325-39.
Thornton JG,
Lilford RJ, Johnston N. Decision analysis in medicine.
BMJ. 1992;304(6834):1099-103.
Tom E, Schulman KA.
Mathematical models in decision analysis. Infect Control
Hosp Epidemiol. 1997 Jan;18(1):65-73.
Topfer L, Parado
A, Menon D, et al. Comparison of literature searches on quality
and costs for health technology assessment using MEDLINE and
EMBASE databases. Int J Technol Assess Health Care.
1999;15(2):297-303.
Torrance GW,
Feeny D. Utilities and quality-adjusted life years. Int J
Technol Assess Health Care.
1989;5(4):559-75.
Tunis SR, Stryer
DB, Clancy CM. Practical clinical trials: increasing the value
of clinical research for decision making in clinical and health
policy. JAMA. 2003;290(12):1624-32.
Tymstra T. The
imperative character of medical technology and the meaning of
'anticipated decision regret.' Int J Technol Assess Health
Care. 1989;5:207-13.
Ubel PA, Nord E, Gold
M, et al. Improving value measurement in cost-effectiveness
analysis. Med Care. 2000;38:892-901.
UK National Health
Service R&D Health Technology Assessment Programme,
2003. http://www.ncchta.org/about/index.shtml.
Accessed June 1, 2003.
University
HealthSystem Consortium. Clinical Practice Advancement
Center. Technology Report: Implementation of Hospital-Based
Technology Assessment. Oak Brook Ill.: UHC Services
Corporation; 1996.
US Congress,
House of Representatives. Committee on Science and
Astronautics. Technology Assessment. Statement of Emilio Q.
Daddario, Chairman, Subcommittee on Science Research and
Development. 90th Cong., 1st sess., Washington, DC;
1967.
US Congress,
Office of Technology Assessment. Technology Assessment in
Business and Government. Summary and Analysis. Washington,
DC: US Government Printing Office; 1977.
US Congress,
Office of Technology Assessment. Strategies for Medical
Technology Assessment. Washington, DC: US Government
Printing Office; 1983.
US Congress,
Office of Technology Assessment. Protecting Privacy in
Computerized Medical Information. Washington, DC: US
Government Printing Office; 1994.
US Department of
Health and Human Services, Agency for Health Care Policy and
Research. Extracranial-Intracranial Bypass to Reduce the
Risk of Ischemic Stroke. Health Technology Assessment
Reports. No. 6. Rockville, Md; 1990.
US Department of
Health and Human Services, Agency for Health Care Policy and
Research. Intermittent Positive Pressure Breathing: Old
Technologies Rarely Die. Rockville, Md;
1993.
US
Preventive Services Task Force. Screening for prostate cancer:
recommendations and rationale. Ann Intern Med.
2002;137:915-6.
van den Broek SA,
van Veldhuisen DJ, de Graeff PA, et al. Comparison between New
York Heart Association classification and peak oxygen
consumption in the assessment of functional status and
prognosis in patients with mild to moderate chronic congestive
heart failure. Am J Cardiol.
1992;70(3):359-63.
Van der Wilt GJ,
Reuzel R, Banta HD. The ethics of assessing health
technologies. Theor Med Bioeth.
2000;21(1):103-15.
van
Houwelingen HC, Arends LR, Stijnen T. Advanced methods in
meta-analysis: multivariate approach and meta-regression.
Stat Med. 2002;21:589-624.
Varmus H, Satcher
D. Ethical complexities of conducting research in developing
countries. N Engl J Med.
1997;337(14):1003-5.
Wakefield DS,
Wakefield BJ. Overcoming barriers to implementation of TQM/CQI
in hospitals: myths and realities. QRB. Quality Review
Bulletin. 1993;19(3):83-8.
Ware JE Jr.,
Sherbourne CD. The MOS 36-item Short Form Health Survey
(SF-36): I. conceptual framework and item selection. Med
Care. 1992;30(6):473-83.
Weinstein MC,
O'Brien B, Hornberger J, et al. Principles of good practice for
decision analytic modeling in health-care evaluation: report of
the ISPOR Task Force on Good Research Practices –
Modeling Studies. Value Health.
2003;6(1):9-17.
Willke RJ, Glick
HA, Polsky D, Schulman K. Estimating country-specific
cost-effectiveness from multinational clinical trials.
Health Economics. 1998;7:481-93.
Wood DE, DeCamp MM.
The National Emphysema Treatment Trial: a paradigm for future
surgical trials. Ann Thorac Surg.
2001;72(2):327-9.
Woolacott NF,
Jones L, Forbes CA, et al. The clinical effectiveness and
cost-effectiveness of bupropion and nicotine replacement
therapy for smoking cessation: a systematic review and economic
evaluation. Health Technol Assess.
2002;6(16):1-245.
World Development Report 1993: Investing in
Health. The World Bank. New York, NY: Oxford University
Press, 1993.
Yoshida EM.
Selecting candidates for liver transplantation: a medical
ethics perspective on the microallocation of a scarce and
rationed resource. Can J Gastroenterol.
1998;12(3):209-15.
Yusuf S, Held P,
Teo KK, Toretsky ER. Selection of patients for randomized
controlled trials: implications of wide or narrow eligibility
criteria. Stat Med. 1990;9(1-2):73-83.